Solid Biosciences (SLDB) Non-Current Assets (2017 - 2026)

Solid Biosciences has disclosed Non-Current Assets across 10 years of filings, most recently posting $26.1 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $26.1 million, down 14.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.1 million (down 14.4% YoY), and the FY2025 annual result was $27.1 million, down 13.64% from the prior year.
• Non-Current Assets came in at $26.1 million for Q1 2026 at Solid Biosciences, down from $27.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $40.6 million in Q4 2022 to a low of $8.9 million in Q1 2022.
• The 5-year median for Non-Current Assets is $33.4 million (2024), against an average of $32.1 million.
• Across the five-year window, Non-Current Assets retreated 18.54% in 2022 and surged 335.67% in 2023, its largest moves.
• Solid Biosciences' Non-Current Assets stood at $40.6 million in 2022, then slipped by 13.32% to $35.2 million in 2023, then decreased by 10.92% to $31.4 million in 2024, then retreated by 13.64% to $27.1 million in 2025, then dropped by 3.61% to $26.1 million in 2026.
• The last three Non-Current Assets figures came in at $26.1 million (Q1 2026), $27.1 million (Q4 2025), and $29.1 million (Q3 2025), per Business Quant data.